A recent meta-analysis further revealed that the approach combining TACE, lenvatinib, and PD-1 inhibitors could significantly improve overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) in patients with advanced HCC, without markedly increasing the risk of treatment-related adverse events of any grade (12). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.